Table IV.
Mean combination index values of NVP-AEW541 when combined with afatinib, erlotinib, crizotinib and paclitaxel in human ovarian cancer cell lines.a
| Mean combination index (effect) | ||||
|---|---|---|---|---|
|
|
||||
| Cell line | NVP-AEW541 + afatinib | NVP-AEW541 + erlotinib | NVP-AEW541 + crizotinib | NVP-AEW541 + paclitaxel |
| SKOV3 | 0.88 (slight synergism) | 1.64 (antagonism) | 0.10 (strong synergism) | 0.96 (nearly additive) |
| CAOV3 | 1.3 (moderate antagonism) | 1.83 (antagonism) | 0.20 (strong synergism) | 0.30 (strong synergism) |
| ES2 | 1.87 (moderate antagonism) | 5.54 (strong antagonism) | 2.5 (strong antagonism) | 0.89 (slight synergism) |
a
The degree of antagonism or synergism was calculated by Calcusyn software. Each value is the mean of three independent experiments.